FOLH1 and prostate carcinoma: Replacement of the his-myc tag by the cys tag as well as coinjection with Gelofusine significantly diminished kidney retention, resulting in excellent tumour-to-kidney ratios, bringing the theranostic potential of JVZ-007 in PSMA-positive prostate cancer within reach.